Cargando…
Evaluation of the use of methylprednisolone and dexamethasone in asthma critically ill patients with COVID-19: a multicenter cohort study
BACKGROUND: Previous studies have shown mortality benefits with corticosteroids in Coronavirus disease-19 (COVID-19). However, there is inconsistency regarding the use of methylprednisolone over dexamethasone in COVID-19, and this has not been extensively evaluated in patients with a history of asth...
Autores principales: | , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10463591/ https://www.ncbi.nlm.nih.gov/pubmed/37641042 http://dx.doi.org/10.1186/s12890-023-02603-4 |
_version_ | 1785098267154972672 |
---|---|
author | Al Sulaiman, Khalid Aljuhani, Ohoud Korayem, Ghazwa B. Altebainawi, Ali Alharbi, Reham Assadoon, Maha Vishwakarma, Ramesh Ismail, Nadia H. Alshehri, Asma A. Al Mutairi, Faisal E. AlFaifi, Mashael Alharthi, Abdullah F. Alenazi, Abeer A. Alalawi, Mai Al Zumai, Omar Al Haji, Hussain Al Dughaish, Sarah T. Alawaji, Abdulrahman S. Alhaidal, Haifa A. Al Ghamdi, Ghassan |
author_facet | Al Sulaiman, Khalid Aljuhani, Ohoud Korayem, Ghazwa B. Altebainawi, Ali Alharbi, Reham Assadoon, Maha Vishwakarma, Ramesh Ismail, Nadia H. Alshehri, Asma A. Al Mutairi, Faisal E. AlFaifi, Mashael Alharthi, Abdullah F. Alenazi, Abeer A. Alalawi, Mai Al Zumai, Omar Al Haji, Hussain Al Dughaish, Sarah T. Alawaji, Abdulrahman S. Alhaidal, Haifa A. Al Ghamdi, Ghassan |
author_sort | Al Sulaiman, Khalid |
collection | PubMed |
description | BACKGROUND: Previous studies have shown mortality benefits with corticosteroids in Coronavirus disease-19 (COVID-19). However, there is inconsistency regarding the use of methylprednisolone over dexamethasone in COVID-19, and this has not been extensively evaluated in patients with a history of asthma. This study aims to investigate and compare the effectiveness and safety of methylprednisolone and dexamethasone in critically ill patients with asthma and COVID-19. METHODS: The primary endpoint was the in-hospital mortality. Other endpoints include 30-day mortality, respiratory failure requiring mechanical ventilation (MV), acute kidney injury (AKI), acute liver injury, length of stay (LOS), ventilator-free days (VFDs), and hospital-acquired infections. Propensity score (PS) matching, and regression analyses were used. RESULTS: A total of one hundred-five patients were included. Thirty patients received methylprednisolone, whereas seventy-five patients received dexamethasone. After PS matching (1:1 ratio), patients who received methylprednisolone had higher but insignificant in-hospital mortality in both crude and logistic regression analysis, [(35.0% vs. 18.2%, P = 0.22) and (OR 2.31; CI: 0.56 – 9.59; P = 0.25), respectively]. There were no statistically significant differences in the 30-day mortality, respiratory failure requiring MV, AKI, acute liver injury, ICU LOS, hospital LOS, and hospital-acquired infections. CONCLUSIONS: Methylprednisolone in COVID-19 patients with asthma may lead to increased in-hospital mortality and shorter VFDs compared to dexamethasone; however, it failed to reach statistical significance. Therefore, it is necessary to interpret these data cautiously, and further large-scale randomized clinical trials are needed to establish more conclusive evidence and support these conclusions. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12890-023-02603-4. |
format | Online Article Text |
id | pubmed-10463591 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-104635912023-08-30 Evaluation of the use of methylprednisolone and dexamethasone in asthma critically ill patients with COVID-19: a multicenter cohort study Al Sulaiman, Khalid Aljuhani, Ohoud Korayem, Ghazwa B. Altebainawi, Ali Alharbi, Reham Assadoon, Maha Vishwakarma, Ramesh Ismail, Nadia H. Alshehri, Asma A. Al Mutairi, Faisal E. AlFaifi, Mashael Alharthi, Abdullah F. Alenazi, Abeer A. Alalawi, Mai Al Zumai, Omar Al Haji, Hussain Al Dughaish, Sarah T. Alawaji, Abdulrahman S. Alhaidal, Haifa A. Al Ghamdi, Ghassan BMC Pulm Med Research BACKGROUND: Previous studies have shown mortality benefits with corticosteroids in Coronavirus disease-19 (COVID-19). However, there is inconsistency regarding the use of methylprednisolone over dexamethasone in COVID-19, and this has not been extensively evaluated in patients with a history of asthma. This study aims to investigate and compare the effectiveness and safety of methylprednisolone and dexamethasone in critically ill patients with asthma and COVID-19. METHODS: The primary endpoint was the in-hospital mortality. Other endpoints include 30-day mortality, respiratory failure requiring mechanical ventilation (MV), acute kidney injury (AKI), acute liver injury, length of stay (LOS), ventilator-free days (VFDs), and hospital-acquired infections. Propensity score (PS) matching, and regression analyses were used. RESULTS: A total of one hundred-five patients were included. Thirty patients received methylprednisolone, whereas seventy-five patients received dexamethasone. After PS matching (1:1 ratio), patients who received methylprednisolone had higher but insignificant in-hospital mortality in both crude and logistic regression analysis, [(35.0% vs. 18.2%, P = 0.22) and (OR 2.31; CI: 0.56 – 9.59; P = 0.25), respectively]. There were no statistically significant differences in the 30-day mortality, respiratory failure requiring MV, AKI, acute liver injury, ICU LOS, hospital LOS, and hospital-acquired infections. CONCLUSIONS: Methylprednisolone in COVID-19 patients with asthma may lead to increased in-hospital mortality and shorter VFDs compared to dexamethasone; however, it failed to reach statistical significance. Therefore, it is necessary to interpret these data cautiously, and further large-scale randomized clinical trials are needed to establish more conclusive evidence and support these conclusions. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12890-023-02603-4. BioMed Central 2023-08-28 /pmc/articles/PMC10463591/ /pubmed/37641042 http://dx.doi.org/10.1186/s12890-023-02603-4 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Al Sulaiman, Khalid Aljuhani, Ohoud Korayem, Ghazwa B. Altebainawi, Ali Alharbi, Reham Assadoon, Maha Vishwakarma, Ramesh Ismail, Nadia H. Alshehri, Asma A. Al Mutairi, Faisal E. AlFaifi, Mashael Alharthi, Abdullah F. Alenazi, Abeer A. Alalawi, Mai Al Zumai, Omar Al Haji, Hussain Al Dughaish, Sarah T. Alawaji, Abdulrahman S. Alhaidal, Haifa A. Al Ghamdi, Ghassan Evaluation of the use of methylprednisolone and dexamethasone in asthma critically ill patients with COVID-19: a multicenter cohort study |
title | Evaluation of the use of methylprednisolone and dexamethasone in asthma critically ill patients with COVID-19: a multicenter cohort study |
title_full | Evaluation of the use of methylprednisolone and dexamethasone in asthma critically ill patients with COVID-19: a multicenter cohort study |
title_fullStr | Evaluation of the use of methylprednisolone and dexamethasone in asthma critically ill patients with COVID-19: a multicenter cohort study |
title_full_unstemmed | Evaluation of the use of methylprednisolone and dexamethasone in asthma critically ill patients with COVID-19: a multicenter cohort study |
title_short | Evaluation of the use of methylprednisolone and dexamethasone in asthma critically ill patients with COVID-19: a multicenter cohort study |
title_sort | evaluation of the use of methylprednisolone and dexamethasone in asthma critically ill patients with covid-19: a multicenter cohort study |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10463591/ https://www.ncbi.nlm.nih.gov/pubmed/37641042 http://dx.doi.org/10.1186/s12890-023-02603-4 |
work_keys_str_mv | AT alsulaimankhalid evaluationoftheuseofmethylprednisoloneanddexamethasoneinasthmacriticallyillpatientswithcovid19amulticentercohortstudy AT aljuhaniohoud evaluationoftheuseofmethylprednisoloneanddexamethasoneinasthmacriticallyillpatientswithcovid19amulticentercohortstudy AT korayemghazwab evaluationoftheuseofmethylprednisoloneanddexamethasoneinasthmacriticallyillpatientswithcovid19amulticentercohortstudy AT altebainawiali evaluationoftheuseofmethylprednisoloneanddexamethasoneinasthmacriticallyillpatientswithcovid19amulticentercohortstudy AT alharbireham evaluationoftheuseofmethylprednisoloneanddexamethasoneinasthmacriticallyillpatientswithcovid19amulticentercohortstudy AT assadoonmaha evaluationoftheuseofmethylprednisoloneanddexamethasoneinasthmacriticallyillpatientswithcovid19amulticentercohortstudy AT vishwakarmaramesh evaluationoftheuseofmethylprednisoloneanddexamethasoneinasthmacriticallyillpatientswithcovid19amulticentercohortstudy AT ismailnadiah evaluationoftheuseofmethylprednisoloneanddexamethasoneinasthmacriticallyillpatientswithcovid19amulticentercohortstudy AT alshehriasmaa evaluationoftheuseofmethylprednisoloneanddexamethasoneinasthmacriticallyillpatientswithcovid19amulticentercohortstudy AT almutairifaisale evaluationoftheuseofmethylprednisoloneanddexamethasoneinasthmacriticallyillpatientswithcovid19amulticentercohortstudy AT alfaifimashael evaluationoftheuseofmethylprednisoloneanddexamethasoneinasthmacriticallyillpatientswithcovid19amulticentercohortstudy AT alharthiabdullahf evaluationoftheuseofmethylprednisoloneanddexamethasoneinasthmacriticallyillpatientswithcovid19amulticentercohortstudy AT alenaziabeera evaluationoftheuseofmethylprednisoloneanddexamethasoneinasthmacriticallyillpatientswithcovid19amulticentercohortstudy AT alalawimai evaluationoftheuseofmethylprednisoloneanddexamethasoneinasthmacriticallyillpatientswithcovid19amulticentercohortstudy AT alzumaiomar evaluationoftheuseofmethylprednisoloneanddexamethasoneinasthmacriticallyillpatientswithcovid19amulticentercohortstudy AT alhajihussain evaluationoftheuseofmethylprednisoloneanddexamethasoneinasthmacriticallyillpatientswithcovid19amulticentercohortstudy AT aldughaishsaraht evaluationoftheuseofmethylprednisoloneanddexamethasoneinasthmacriticallyillpatientswithcovid19amulticentercohortstudy AT alawajiabdulrahmans evaluationoftheuseofmethylprednisoloneanddexamethasoneinasthmacriticallyillpatientswithcovid19amulticentercohortstudy AT alhaidalhaifaa evaluationoftheuseofmethylprednisoloneanddexamethasoneinasthmacriticallyillpatientswithcovid19amulticentercohortstudy AT alghamdighassan evaluationoftheuseofmethylprednisoloneanddexamethasoneinasthmacriticallyillpatientswithcovid19amulticentercohortstudy |